Heather A. Berger bought $4,866 of DSGN
director at Design Therapeutics, Inc.. 1,300 shares at an average of $3.74, traded Mar 25, 2024, filed Mar 25, 2024.
Score components
- +15RoleDirector
- 0Trade size$5k at market
- +8Relative to holdingsFirst purchase: no shares before this trade
- +8Price context54% below the 52-week high
- +8Cluster2 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-24-009062, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 25, 2024 | POpen-market purchase Common Stock | +1,300 | $3.74 | $4,866 | 1,300 | Mar 25, 2024 |
Related signals
Other insiders at Design Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 45Moderate | DSGNsell Design Therapeutics, Inc. | Arsani William director | $3.0M 562,627 shares | -19% | |
| 20Weak | DSGNsell Design Therapeutics, Inc. | Deepa Prasad director | $24k 3,806 shares | -16% | |
| 49Moderate | Design Therapeutics, Inc. | John P. Schmid director | $100k 26,965 shares | - |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.